VEEV vs MEDP

For growth investors, Medpace Holdings, Inc.

(MEDP) is the stronger pick with 20. 0% revenue growth year-over-year, versus 16. 3% for Veeva Systems Inc. (VEEV). Medpace Holdings, Inc. (MEDP) offers the better valuation at 27. 9x trailing P/E (25. 1x forward), making it the more compelling value choice. Analysts rate Veeva Systems Inc. (VEEV) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medpace Holdings, Inc.

(MEDP) is the cheapest at 27. 9x versus Veeva Systems Inc. at 30. 8x. On forward P/E, Veeva Systems Inc. is actually cheaper at 18. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Medpace Holdings, Inc. wins at 0. 79x versus Veeva Systems Inc. 's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +160. 4%, compared to -35. 2% for Veeva Systems Inc. (VEEV). Over 10 years, the gap is even starker: MEDP returned +1436% versus VEEV's +519. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Veeva Systems Inc.

(VEEV) is the lower-risk stock at 0. 77β versus Medpace Holdings, Inc. 's 1. 26β — meaning MEDP is approximately 62% more volatile than VEEV relative to the S&P 500. On balance sheet safety, Veeva Systems Inc. (VEEV) carries a lower debt/equity ratio of 1% versus 55% for Medpace Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Medpace Holdings, Inc.

(MEDP) is pulling ahead at 20. 0% versus 16. 3% for Veeva Systems Inc. (VEEV). On earnings-per-share growth, the picture is similar: Veeva Systems Inc. grew EPS 25. 9% year-over-year, compared to 21. 0% for Medpace Holdings, Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Veeva Systems Inc.

(VEEV) is the more profitable company, earning 28. 4% net margin versus 17. 8% for Medpace Holdings, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VEEV leads at 28. 7% versus 21. 1% for MEDP. At the gross margin level — before operating expenses — VEEV leads at 75. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Medpace Holdings, Inc. (MEDP) is the more undervalued stock at a PEG of 0. 79x versus Veeva Systems Inc. 's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Veeva Systems Inc. (VEEV) trades at 18. 9x forward P/E versus 25. 1x for Medpace Holdings, Inc. — 6. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 67. 4% to $280. 10.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1436% 10Y return). Both have compounded well over 10 years (MEDP: +1436%, VEEV: +519. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.